Tobacco use is the greatest preventable cause of cancer in the United States, accounting for almost one third of all cancer-related deaths and 90% of deaths from lung cancer. Despite widespread knowledge of these risks, tobacco use prevalence rates are 20% in the United States and up to 30% to 50% in the developing world (1, 2). Nicotine, the addictive chemical in tobacco, produces a biological dependence (3), and therefore, even with the most efficacious medications available, only one in four smokers is able to maintain long-term abstinence (4). Persistent tobacco use is common even following a diagnosis of tobacco-related cancer and is associated with poorer outcomes of radiation therapy and chemotherapy and with increased risk of second primary malignancies (5). Although smoking cessation is optimal, it may not be realistic for all patients. Therefore, it is essential to gain a better understanding of the cellular and molecular mechanisms through which tobacco exposure contributes to cancer pathogenesis and outcomes, and to develop targeted prevention and therapeutic approaches.

Toward this end, a study reported by Gumus et al. (6) in this issue of the journal characterized gene expression profiles in the oral mucosa of smokers and nonsmokers and validated their findings by examining the in vitro effects of tobacco smoke condensate on gene expression in an oral leukoplakia cell line. Another related study also reported in this issue of the journal was conducted by Zhang et al. (7), who compared gene expression in cells obtained from bronchial brushes from never, current, and former smokers. Smoking effects on global gene expression were common across these studies. Certain genes (CYP1A1 and CYP1B1) that were up-regulated in buccal oral specimens of smokers were part of a larger group (CYP1A1, CYP1B1, ALDH3A1, NQO1, and AKR1C1) up-regulated following in vitro exposure to tobacco smoke condensate (6) and in the airway cells of smokers (7). Zhang and colleagues provide further in vivo evidence that many of these genes are down-regulated in persons who reported quitting smoking at least 1 year before the assessment (CYP1B1, AKR1C1, AKR1C2, AKR1B10, and ALDH3A1). Many of these same genes were previously shown to be overexpressed in oral cancer cells exposed to tobacco smoke condensate (8), in bronchial epithelial cells of smokers, and in patients' non–small cell lung carcinoma cells (9, 10). The effects are also consistent with the effects of smoking on the airway transcriptome (11, 12). Taken together, these findings identify important tobacco smoke exposure response genes. The studies of Gumus et al. and Zhang et al. in this issue of the journal provide an elegant illustration of the value of cross-model (preclinical and clinical) validation in translational cancer prevention research.

These findings are highly significant for our understanding of cancer etiology. Many of the altered enzymes play pivotal roles in the metabolism/activation of polycyclic aromatic hydrocarbons (PAH; refs. 1316), which are tobacco carcinogens. Their up-regulation likely results in increased metabolism of PAH to biologically reactive intermediates that can lesion DNA. Importantly, CYP1A1 and CYP1B1 are induced when PAH bind to the aryl hydrocarbon receptor, which turns on gene transcription via the xenobiotic response element (refs. 13, 17, 18; Fig. 1A). CYP1A1/CYP1B1 are ultimately responsible for the monoxygenation of PAH to yield diol-epoxides, which form covalent bulky adducts with DNA that lead to mutation (19, 20). Paradoxically, studies with CYP1A1 and CYP1B1 knockout mice show that these enzymes protect against benzo[a]pyrene (B[a]P) toxicity because in their absence, diol-epoxide DNA adduct levels are even higher (2123). This outcome is evident in human bronchoalveolar (H358) cells where cells induced to express CYP1B1 produced less anti-B[a]P-diol epoxide-N2-dGuo adducts than uninduced cells (24). This suggests that in the absence of CYP1A1/CYP1B1, lower clearance of B[a]P leads to the formation of more diol-epoxide DNA adducts and that CYP1A1/CYP1B1 induction is protective.

Fig. 1

Significance of tobacco exposure response genes. A, up-regulation of CYP1A1/CYP1B1 and AKR genes leads to a decrease in diol-epoxide DNA adducts and an increase in oxidative DNA damage. B, up-regulation of CYP1A1/CYP1B1 and AKR genes leads to an increase in reactive oxygen species and lipid peroxidation, which is counteracted by induction of ALDH3A1 and the AKR gene battery. C, up-regulation of AKR1B10 via the antioxidant response element leads to a loss of retinoic acid signaling. D, up-regulation of CYP1A1/1B1 and AKR genes leads to an increase in cancer chemotherapeutic drug resistance. AhR, aryl hydrocarbon receptor; ARE, antioxidant response element; 4-HNE, 4-hydroxy-2-nonenal; ROS, reactive oxygen species; XRE, xenobiotic response element.

Fig. 1

Significance of tobacco exposure response genes. A, up-regulation of CYP1A1/CYP1B1 and AKR genes leads to a decrease in diol-epoxide DNA adducts and an increase in oxidative DNA damage. B, up-regulation of CYP1A1/CYP1B1 and AKR genes leads to an increase in reactive oxygen species and lipid peroxidation, which is counteracted by induction of ALDH3A1 and the AKR gene battery. C, up-regulation of AKR1B10 via the antioxidant response element leads to a loss of retinoic acid signaling. D, up-regulation of CYP1A1/1B1 and AKR genes leads to an increase in cancer chemotherapeutic drug resistance. AhR, aryl hydrocarbon receptor; ARE, antioxidant response element; 4-HNE, 4-hydroxy-2-nonenal; ROS, reactive oxygen species; XRE, xenobiotic response element.

Close modal

PAH trans-dihydrodiols formed en route to diol-epoxides are also oxidized by AKR1C1 or AKR1C2 to yield electrophilic and redox active PAH o-quinones (16, 25, 26). B[a]P-7,8-dione, because it is redox active, enters into futile redox cycles to amplify the formation of reactive oxygen species that results in oxidatively damaged DNA (e.g., 8-oxo-dGuo, a highly mutagenic lesion; refs. 27, 28). The AKR-generated B[a]P-7,8-dione is a ligand for the aryl hydrocarbon receptor and will induce CYP1A1 and CYP1B1 still further (29, 30). Moreover, the B[a]P-7,8-dione and the reactive oxygen species it generates induce AKR1C1-AKR1C3 genes via their antioxidant response elements (31, 32). Nrf2 the transcription factor that binds to the antioxidant response element also induces the aryl hydrocarbon receptor (AhR) gene (33). Thus, tobacco exposure leads to the induction of the CYP1A1 /CYP1B1 and AKR genes to stimulate B[a]P metabolism. On balance, this could result in less diol-epoxide DNA adducts and the formation of more B[a]P-7,8-dione and reactive oxygen species that will lead to mutagenic oxidative DNA damage.

Another gene that showed altered expression was ALDH3A1. When coupled with the overexpression of AKR1C1, AKR1C2, AKR1B10, and NQO1 genes, another outcome of chronic tobacco exposure is to mount a counter-response to oxidative stress (Fig. 1B). Tobacco smoke leads to oxidative stress due to the presence of benzoquinone and heavy metals and the production of redox-active PAH o-quinones, which is AKR mediated (see above). Each of these up-regulated genes contains an antioxidant response element in their gene promoters (32, 34, 35). A consequence of oxidative stress is the formation of lipid peroxides that can break down to form reactive bifunctional electrophiles (e.g., 4-hydroxy-2-nonenal and 4-oxo-2-nonenal; refs. 36, 37). Induction of these genes provides a route to the detoxification of these reactive lipid aldehydes.

One remaining gene that deserves comment is the altered expression of AKR1B10 (small intestine like aldose reductase; Fig. 1C). Whereas this gene can protect against the toxic effects of lipid aldehydes, it has another function (3840). It is the most catalytically efficient of all the known all-trans-retinal reductases (40). Elimination of retinal as retinol prevents the conversion of retinal to retinoic acid. Retinoic acid is a ligand for retinoid acid receptor and retinoid X receptor, and activation of these nuclear receptors leads to cell differentiation (41). If retinoid acid receptor and retinoid X receptor are deprived of their ligand, this could lead to a pro-proliferative response. In fact, retinoid acid receptor and retinoid X receptor are often lost in lung cancer cell lines, suggesting that there is a coordinated loss of retinoic acid signaling (42).

Identification of tobacco exposure response genes has important implications for chemoprevention and chemotherapy of tobacco-related cancers in smokers. At first glance, inhibition of the CYP1A1/CYP1B1 genes might be anticipated to be beneficial because it could reduce the level of diol-epoxides. However, the phenotype of CYP1A1/CYP1B1 knockout mice indicates that this will increase PAH toxicity, and this should be avoided (2123). Clearly, the overexpression of AKRs in smokers is a double-edged sword. On the one hand, this could lead to increased bioactivation of PAH and DNA mutation, and on the other hand, they are part of a counter-response to oxidative stress and lipid peroxidation. AKR genes are regulated by an antioxidant response element, and chemopreventive strategies that target this mechanism of gene induction (e.g., R-sulforaphane) should be considered with caution because it is uncertain that they will be harmful or beneficial in the context of lung cancer (43). Strategies aimed at the inhibition of AKRs may be more effective because although this will attenuate the detoxification of 4-hydroxy-2-nonenal, this may be compensated for by redundancy in the detoxifying enzymes (e.g., ALDH3A1 and glutathione S-transferases) that compete for 4-hydroxy-2-nonenal. Approved drugs that are potent inhibitors of the AKRs are the nonsteroidal anti-inflammatory drugs (44).

If oxidative stress is a driving component of the lung carcinogenic process, antioxidant strategies may also be desirable. Two high profile clinical trials addressed the use of antioxidant vitamins: The Alpha-Tocopherol Beta-Carotene Prevention Study (45) and the Carotene and Retinol Efficacy Trial (46). Both studies revealed that lung cancer risk was significantly increased in heavy smokers receiving β-carotene (47). The altered expression of AKR1B10, reported to be coupled with the high overexpression of AKR1B10 seen in non–small cell lung carcinoma by Fukumoto et al. (9), suggests why chemopreventive studies that target retinoid X receptor and retinoid acid receptor are likely to fail. AKR1B10 will rapidly eliminate retinal as retinol and prevent formation of retinoic acid. By contrast, in the Alpha-Tocopherol Beta-Carotene study, high serum α-tocopherol was associated with lower lung cancer incidence, although the effect was stronger in smokers with less cumulative tobacco exposure (48).

Overexpression of CYP1B1 and AKRs may also contribute to cancer chemotherapeutic drug resistance, and therefore chronic smokers with lung cancer may have lower response rates on these therapies (Fig. 1D). CYP1B1 is implicated in the metabolic clearance of docetaxel, gefitinib, and erlotinib (49, 50). In addition, AKR1C1 is overexpressed in HT29 colon cancer cells that are resistant to the glutathione S-transferase inhibitor ethacrynic acid (51). AKR1C1 and AKR1C2 genes are overexpressed in non–small cell lung carcinoma in patients with poor response to anti-pyrimidine therapy (52), and AKR1C1 and AKR1C2 are overexpressed in ovarian cancer cell lines resistant to cisplatin (53, 54). In the latter case, cisplatin resistance could be accomplished by transfection of AKR1C1. Because cisplatin is widely used for non–small cell lung carcinoma, this raises the prospect that its efficacy could be improved by the coadministration of nonsteroidal anti-inflammatory drugs, which are known inhibitors of AKR isozymes.

To increase our understanding of the molecular mechanisms through which tobacco smoke exposure influences the efficacy of cancer prevention and therapeutic agents, a more rigorous exposure measurement, beyond the traditional smoking pack-years assessment, is needed (5). This should include ongoing assessment of tobacco exposure following diagnosis, biochemical verification of self-reported use using biomarkers (e.g., cotinine, 3′-trans-hydroxycotinine, and 3-hydroxy-B[a]P), and use of pharmacotherapy to reduce tobacco exposure.

These emerging data raise exciting prospects for translation of genomics research on smoking exposure to practice. As shown by Beane et al. (55) in this issue, the integration of integrated clinical and genomic profiling information can provide a powerful risk assessment “clinicogenomic” tool that could be translated to the clinical setting. Genomic profiling strategies may also facilitate prevention of tobacco-related cancer by facilitating smoking cessation. For example, feedback to smokers about gene expression profiling of oral or airway cells may serve as a motivational intervention for smoking cessation (56). In addition, new data also support the potential application of profiling of inherited genomic variation to predict the risk of smoking relapse and to optimize smoking cessation therapy (57). Finally, the studies published in this issue identify genomic alterations associated with smoking exposure, and the mechanisms through which these genes alter therapeutic response will hopefully identify agents that can be used by smokers for cancer prevention and treatment.

No potential conflicts of interest were disclosed.

1
CDC
Cigarette smoking among adults—United States, 2004
.
MMWR Morb Mortal Wkly Rep
2005
;
54
:
1121
4
.
2
MacKay
M
,
Eriksen
M
The tobacco atlas. World Health Organization;
2001
.
3
Lerman
C
,
Lesage
MG
,
Perkins
KA
, et al
Translational research in medication development for nicotine dependence
.
Nat Rev Drug Discov
2007
;
9
:
746
62
.
4
Schnoll
R
,
Lerman
C
Current and emerging pharmacotherapies for treating tobacco dependence
.
Expert Opin Emerg Drugs
2006
;
11
:
1
16
.
5
Gritz
E
,
Dresler
C
,
Sarna
L
Smoking, the missing drug interaction in clinical trials: ignoring the obvious
.
Cancer Epidemiol Biomarkers Prev
2005
;
14
:
2287
93
.
6
Gumus
ZH
,
Du
B
,
Kacker
A
, et al
Effects of tobacco smoke on gene expression and cellular pathways in a cellular model of oral leukoplakia
.
Cancer Prev Res.
In press
.
7
Zhang
L
,
Lee
JJ
,
Tang
H
, et al
Impact of smoking cessation on global gene expression in the bronchial epithelium of chronic smokers
.
Cancer Prev Res.
In press
.
8
Nagaraj
N
,
Beckers
S
,
Meansh
JK
, et al
Cigarette smoke condensate induces cytochrome P450 and aldo keto reductases in oral cancer cells
.
Toxicol Lett
2006
;
165
:
182
94
.
9
Fukumoto
S-I
,
Yamauchi
N
,
Moriguchi
H
, et al
Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas
.
Clin Cancer Res
2005
;
11
:
1776
85
.
10
Woenckhaus
M
,
Klein-Hitpass
L
,
Grepmeier
U
, et al
Smoking and cancer-related gene expression in bronchial epithelium and non-small cell lung cancer
.
J Pathol
2006
;
210
:
192
204
.
11
Spira
A
,
Beane
J
,
Shah
V
, et al
Effects of cigarette smoke on the human airway epithelial cell transcriptome
.
Proc Natl Acad Sci U S A
2004
;
101
:
10143
8
.
12
Beane
J
,
Sebastiani
P
,
Liu
G
, et al
Reversible and permanent effects of tobacco smoke exposure on airway epithelial gene expression
.
Genome Biol
2007
;
8
:
R201
.
13
Till
M
,
Riebniger
D
,
Schmitz
HJ
, et al
Potency of various polycyclic aromatic hydrocarbons as inducers of CYP1A1 in rat hepatocyte cultures
.
Chem Biol Interact
1999
;
117
:
135
50
.
14
Sutter
TR
,
Tang
YM
,
Hayes
CL
, et al
Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2
.
J Biol Chem
1994
;
269
:
13092
9
.
15
Shimada
T
,
Hayes
CL
,
Yamazaki
H
, et al
Activation of chemically diverse procarcinogens by human cytochrome P450 1B1
.
Cancer Res
1996
;
56
:
2979
84
.
16
Palackal
NT
,
Lee
S-H
,
Harvey
RG
, et al
Activation of polycyclic aromatic hydrocarbon trans-dihydrodiol proximate carcinogens by human aldo-keto reductase (AKR1C) enzymes and their functional overexpression in human lung carcinoma (A549) cells
.
J Biol Chem
2002
;
277
:
24799
808
.
17
Denison
MS
,
Fisher
JM
,
Whitlock
JP
The DNA recognition site for the dioxin-Ah receptor complex. Nucleotide sequence and functional analysis
.
J Biol Chem
1988
;
263
:
17221
4
.
18
Denison
MS
,
Fisher
JM
,
Whitlock
JP
Protein-DNA interactions at recognition sites for the dioxin-Ah receptor complex
.
J Biol Chem
1989
;
264
:
16478
82
.
19
Conney
AH
Induction of microsomal enzymes by foreign chemicals and carcinogenesis by polycyclic aromatic hydrocarbons. G.H.A. Clowes Memorial Lecture
.
Cancer Res
1982
;
42
:
4875
917
.
20
Gelboin
HV
Benzo[a]pyrene metabolism, activation and carcinogenesis: role and regulation of mixed function oxidases and related enzymes
.
Physiol Rev
1980
;
60
:
1107
66
.
21
Uno
S
,
Dalton
TP
,
Shertzer
HG
, et al
Benzo[a]pyrene-induced toxicity: paradoxical protection in Cyp1a1(−/−) knockout mice having increased heaptic B[a]P-DNA adduct levels
.
Biochem Biophys Res Commun
2001
;
289
:
1049
56
.
22
Uno
S
,
Dalton
TP
,
Derkenne
S
, et al
Oral exposure to benzo[a]pyrene in the mouse: detoxication by inducible cytochrome P450 is more important than metabolic activation
.
Mol Pharmacol
2004
;
65
:
1225
37
.
23
Uno
S
,
Dalton
TP
,
Dragin
N
, et al
Oral benzo[a]pyrene in Cyp1 knockout mouse lines: CYP1A1 important in detoxication, CYP1B1 metabolism required for immune damage independent of total body burden and clearance rate
.
Mol Pharmacol
2006
;
69
:
1103
14
.
24
Ruan
Q
,
Gelhaus
SL
,
Penning
TM
, et al
Aldo-keto reductase- and cytochrome P450-dependent formation of benzo[a]pyrene-derived DNA adducts in human bronchoalveolar cells
.
Chem Res Toxicol
2007
;
20
:
424
31
.
25
Smithgall
TE
,
Harvey
RG
,
Penning
TM
Spectroscopic identification of ortho-quinones as the products of polycyclic aromatic trans-dihydrodiol oxidation catalyzed by dihydrodiol dehydrogenase. A potential route of proximate carcinogen metabolism
.
J Biol Chem
1988
;
263
:
1814
20
.
26
Burczynski
ME
,
Harvey
RG
,
Penning
TM
Expression and characterization of four recombinant human dihydrodiol dehydrogenase isoforms: oxidation of trans-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene to the activated o-quinone metabolite benzo[a]pyrene-7,8-dione
.
Biochemistry
1998
;
37
:
6781
90
.
27
Park
J-H
,
Troxel
AB
,
Harvey
RG
, et al
Polycyclic aromatic hydrocarbon (PAH) o-quinones produced by the aldo-keto reductases (AKRs) generate abasic sites, oxidized pyrimidines, and 8-oxo-dGuo via reactive oxygen species
.
Chem Res Toxicol
2006
;
19
:
719
28
.
28
Nakabeppu
Y
,
Sakumi
K
,
Sakamoto
K
, et al
Mutagenesis and carcinogenesis by oxidized nucleic acids
.
Biol Chem
2006
;
387
:
373
9
.
29
Burczynski
ME
,
Penning
TM
Genotoxic polycyclic aromatic hydrocarbon ortho-quinones generated by aldo-keto reductases induce CYP1A1 via nuclear translocation of the aryl hydrocarbon receptor
.
Cancer Res
2000
;
60
:
908
15
.
30
Jiang
H
,
Vudathala
DK
,
Blair
IA
, et al
Competing roles of aldo-keto reductase 1A1 and cytochrome P4501B1 in benzo[a]pyrene-7,8-diol activation in human bronchoalveolar H358 cells: role of AKRs in P4501B1 induction
.
Chem Res Toxicol
2006
;
19
:
68
78
.
31
Burczynski
ME
,
Lin
H-K
,
Penning
TM
Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenases
.
Cancer Res
1999
;
59
:
607
14
.
32
Lou
H
,
Du
S
,
Ji
Q
, et al
Induction of AKR1C2 by Phase II inducers: identification of a distal consensus antioxidant response element regulated by Nrf2
.
Mol Pharmacol
2006
;
69
:
1662
72
.
33
Shin
S
,
Wakabayashi
N
,
Misra
V
, et al
Nrf2 modulates aryl hydrocarbon receptor signaling: influence on adipogenesis
.
Mol Cell Biol
2007
;
27
:
7188
97
.
34
Penning
TM
,
Drury
J
Human aldo-keto reductases. Function, gene regulation and single nucleotide polymorphisms
.
Arch Biochem Biophys
2007
;
464
:
241
50
.
35
Sreerama
L
,
Sladek
NE
Three different stable human breast adenocarcinoma sublines that overexpress ALDH3A1 and certain other enzymes, apparently as a consequence of constititutively up-regulated gene transcription mediated by transactivated EpREs (electrophile responsive elements) present in the 5′-upstream regions of these genes
.
Chem Biol Interact
2001
;
130–2
:
247
69
.
36
Esterbauer
HM
,
Schauer
RJ
,
Zollner
H
Chemistry and biochemistry of 4-hydroxynonenal, malondialdehyde and related aldehydes
.
Free Radic Biol Med
1991
;
11
:
81
128
.
37
Esterbauer
H
Cytotoxocity and genotoxicity of lipid oxidation products
.
Am J Clin Nutr
1993
;
57
:
779
85S
.
38
Cao
D
,
Fan
ST
,
Chung
SSM
Identification and characterization of a novel human aldose reductase-like gene
.
J Biol Chem
1998
;
273
:
11429
35
.
39
Yan
R
,
Zu
X
,
Ma
J
Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cells: implication for cancer intervention
.
Int J Cancer
2007
;
121
:
2301
6
.
40
Gallego
O
,
Belyaeva
OV
,
Porte
S
, et al
Comparative functional analysis of human medium chain dehydrogenasess, short-chain dehydrogenases and aldo-keto reductases with retinoids
.
Biochem J
2006
;
399
:
101
9
.
41
Le
Q
,
Dawson
MI
,
Soprano
DR
,
Soprano
KJ
Modulation of retinoic acid receptor function alters the growth inhibitory response of oral SCC cells to retinoids
.
Oncogene
2000
;
19
:
1457
65
.
42
Brabender
J
,
Danneberg
KD
,
Metzger
R
, et al
The role of retinoid X receptor messenger RNA expression in curatively resected non-small cell lung cancer
.
Clin Cancer Res
2002
;
8
:
438
43
.
43
Fahey
JW
,
Talalay
P
Antioxidant functions of sulforaphane: a potent inducer of phase II detoxication enzymes
.
Food Chem Toxicol
1999
;
37
:
973
9
.
44
Penning
TM
,
Talalay
P
Inhibition of a major NAD(P)-linked oxidoreductase from rat liver cytosol by steroidal and nonsteroidal anti-inflammatory agents and by prostaglandins
.
Proc Natl Acad Sci U S A
1983
;
80
:
4504
8
.
45
The α Tocopherol-β Carotene Cancer Prevention Study Group
The effect of vitamin E and β carotene on the incidence of lung cancer and other cancers in male smokers
.
N Engl J Med
1994
;
330
:
1029
35
.
46
Omenn
G
,
Goodman
GE
,
Thronquist
MD
, et al
Effects of combination of β-carotene and vitamin A on lung cancer and cardiovascular disease
.
N Engl J Med
1996
;
334
:
1150
5
.
47
Mayne
ST
,
Lippman
SM
Cigarettes: a smoking gun in cancer chemoprevention
.
J Natl Cancer Inst
2005
;
97
:
1319
21
.
48
Woodson
K
,
Tangrea
JA
,
Barrett
MJ
, et al
Serum α-tocopherol and subsequent risk of lung cancer among male smokers
.
J Natl Cancer Inst
1999
;
91
:
1738
43
.
49
Hamilton
M
,
Wolf
JL
,
Rusk
J
, et al
Effects of smoking on the pharmacokinetics of erlotinib
.
Clin Cancer Res
2006
;
12
:
2166
71
.
50
Li
J
,
Zhao
M
,
He
P
, et al
Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes
.
Clin Cancer Res
2007
;
13
:
3731
7
.
51
Ciaccio
PJ
,
Shen
H
,
Jaiswal
AK
, et al
Modulation of detoxification gene expression in human colon HT29 cells by glutathione-S-transferase inhibitors
.
Mol Pharmacol
1995
;
48
:
639
47
.
52
Hsu
N-Y
,
Ho
H-C
,
Chow
K-C
, et al
Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer
.
Cancer Res
2001
;
61
:
2727
31
.
53
Deng
HB
,
Parekh
HK
,
Chow
KC
, et al
Increased expression of dihydrodiol dehydrogenase induces resistance to cisplatin in human ovarian carcinoma cells
.
J Biol Chem
2002
;
277
:
5035
43
.
54
Deng
HB
,
Adikari
M
,
Parekh
HK
, et al
Ubiquitous induction of resistance to platinum drugs in human ovarian, cervical, germ-cell and lung carcinoma tumor cells overexpressing isoforms 1 and 2 of dihydrodiol dehydrogenase
.
Cancer Chemother Pharmacol
2004
;
54
:
301
7
.
55
Beane
J
,
Sebastiani
P
,
Whitfield
TH
, et al
A prediction model for lung cancer diagnosis that integrates genomic and clinical features
.
Cancer Prev Res.
In press
.
56
McBride
CM
,
Bepler
G
,
Lipkus
IM
, et al
Incorporating genetic susceptibility feedback into a smoking cessation program for African-American smokers with low income
.
Cancer Epidemiol Biomarkers Prev
2002
;
11
:
521
8
.
57
Uhl
GR
,
Liu
QR
,
Drgon
T
, et al
Molecular genetics of successful smoking cessation: convergent genome-wide association results
.
Arch Gen Psychiatry
2008
In press
.

Supplementary data